NCT05424549: A trial that was reported late by Aldeyra Therapeutics, Inc.
This trial has reported, although it was 539 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05424549 |
|---|---|
| Title | A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 9, 2022 |
| Completion date | May 9, 2022 |
| Required reporting date | May 9, 2023, midnight |
| Actual reporting date | Oct. 29, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 539 |